Anti-VEGF Market Size, Share, Trends & Forecast
The Anti-VEGF Market is expanding as the prevalence of retinal disorders increases and healthcare providers adopt targeted therapies for vision-threatening conditions. According to Market Research Future, the global market was valued at USD 25.98 billion in 2024 and is projected to reach USD 41.3 billion by 2035, registering a CAGR of 4.3% during 2025–2035.
Anti-VEGF therapies are widely used in the management of conditions including age-related macular degeneration, diabetic retinopathy, macular edema, and retinal vein occlusion. Increasing awareness and improved diagnosis are helping more patients access appropriate treatment.
An aging global population is also contributing to demand, particularly for therapies addressing age-related eye conditions. At the same time, rising diabetes prevalence is increasing the need for treatments for diabetic retinal complications.
Pharmaceutical companies are investing in improved formulations, delivery systems, and next-generation therapies. These developments are creating opportunities to improve treatment convenience and patient outcomes.
With continued advances in ophthalmology and growing healthcare expenditure, the anti-VEGF market is expected to maintain steady expansion through 2035.